Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-girentuximab
- Development stage
- Phase 3
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**89Zr-DFO-girentuximab** is a radiolabeled monoclonal antibody-based imaging agent used for positron emission tomography (PET) of clear cell renal cell carcinoma (ccRCC). It consists of the chimeric monoclonal antibody girentuximab, which specifically targets carbonic anhydrase IX (CAIX), a protein highly expressed on ccRCC cells. The antibody is conjugated to the chelator desferrioxamine (DFO), which binds the radioisotope zirconium‑89 (^89Zr). After intravenous administration, the agent binds to CAIX-expressing tumor cells, allowing PET/CT imaging to differentiate ccRCC from other renal lesions. This targeted approach enables non-invasive detection and characterization of kidney tumors. Developed as TLX250-CDx and branded as Zircaix, it is under regulatory review for kidney cancer imaging and available through expanded access programs in several countries[3][4][5][7].
- Brand names
- Zircaix
- Other names
- 89Zr-labeled girentuximabZirconium-89 girentuximabZirconium89 girentuximabZirconium 89 girentuximab
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on 89Zr-DFO-girentuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-girentuximab.